[Regulation of the adenylate cyclase system of lymphocytes in patients with therapy-resistant arterial hypertension and during PGE2 administration].
The effects of prostaglandin E2 (PGE2) infusions on lymphocyte beta 2-adrenoceptor-dependent adenylate cyclase (beta 2ARAC) system were studied in 26 patients with resistant hypertension (RH). The density of beta 2-adrenoceptors and their affinity for 1-isoproterenol were measured with 125ICYP and adenylate cyclase activity was determined by alpha-[32P]AMP generation in mononuclear lymphocytes of RH patients before and 1, 7, and 14 days after the last PGE2 infusion. Plasma epinephrine and norepinephrine concentrations were analyzed by using HPLC. The resistance to the four-component drug therapy was overcome with PGE2 infusions in patients, leading to a decrease in lymphocyte beta 2-adrenoceptor density and an increase in beta 2-receptor affinity for catecholamines and in adenylate cyclase activation by stimulating agents. PGE2 infusions unchanged the sensitivity to antihypertensive drugs in patients resulting in an increase in lymphocyte beta 2-adrenoceptor density, a decrease in beta 2-receptor affinity for catecholamines and in adenylate cyclase activation.
Krasnikova
T L
TL
Minchuna
V P
VP
Runikhin
A Iu
AIu
Arabidze
G G
GG
Mazaev
A V
AV
Iudaev
A D
AD
D000262:Adenylyl Cyclases / Q000187:drug effects*; D000328:Adult; D002395:Catecholamines / Q000097:blood; D015232:Dinoprostone / Q000494:pharmacology*; D004351:Drug Resistance; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D007262:Infusions, Intravenous; D008214:Lymphocytes / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*
D002395:Catecholamines; D011943:Receptors, Adrenergic, beta; D000262:Adenylyl Cyclases; D015232:Dinoprostone
Reguliatsiia adenilattsiklaznoĭ sistemy limfotsitov u bol'nykh arterial'noĭ gipertonieĭ, refrakternoĭ k terapii, pri vvedenii pge2.